Sugi Predict

Sugi Predict / Compounds / SCHEMBL29414469

SCHEMBL29414469

SCHEMBL29414469

CC(C)C[C@H](NC(=O)[C@@H](N)CC(C)C)C(=O)N[C@H](C(=O)N[C@@H](CCCN=C(N)N)C(=O)N[C@@H](Cc1ccc(O)cc1)C(=O)N[C@H](C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCCN)C(=O)N[C@H](C(=O)N1CCC[C@H]1C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@H](C(=O)N[C@@H](CO)C(=O)O)C(C)C)C(C)C)[C@@H](C)O)C(C)C

nearest known ligand 0.62

Predicted protein targets (top 6)

geneUniProtsupporting neighboursconfidence
▸ NTSR1 P30989 12/20 0.62
▸ NTSR2 O95665 7/20 0.62
▸ SORT1 Q99523 5/20 0.62
▸ OPRD1 P41143 4/20 0.60
▸ OPRM1 P35372 1/20 0.60
▸ OPRK1 P41145 1/20 0.60

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30361896 0.99 NTSR1 (0.61) NTSR1NTSR2SORT1OPRD1OPRM1
SCHEMBL30294171 0.97 NTSR1 (0.64) NTSR1NTSR2SORT1OPRD1OPRM1
SCHEMBL30361957 0.96 NTSR1 (0.60) NTSR1NTSR2SORT1OPRD1OPRM1
SCHEMBL29894426 0.96 NTSR1 (0.63) NTSR1NTSR2SORT1OPRD1OPRM1
SCHEMBL31151633 0.95 NTSR1 (0.61) NTSR1NTSR2SORT1OPRD1OPRM1
SCHEMBL30361837 0.95 NTSR1 (0.61) NTSR1NTSR2SORT1OPRD1OPRM1
SCHEMBL30623611 0.95 NTSR1 (0.65) NTSR1NTSR2SORT1OPRD1OPRM1
SCHEMBL30361923 0.95 NTSR1 (0.60) NTSR1NTSR2SORT1OPRD1OPRM1
SCHEMBL31151473 0.94 OPRD1 (0.61) OPRD1OPRM1OPRK1
SCHEMBL31151446 0.94 NTSR1 (0.59) NTSR1NTSR2SORT1OPRD1OPRM1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4713002-A1 PEPTIDES FOR USE IN THE TREATMENT OF SARCOMA Forssmann, Wolf-Georg (DE) 2026-03-25 — — EP disclosed
EP-4501347-A1 PEPTIDES FOR USE IN THE TREATMENT OF CENTRAL NERVOUS SYSTEM DISORDERS Forssmann, Wolf-Georg (DE) 2025-02-05 — — EP disclosed
EP-4501348-A1 PEPTIDES FOR USE IN THE IMPROVEMENT OF WELL-BEING Forssmann, Wolf-Georg (DE) 2025-02-05 — — EP disclosed
WO-2024235986-A1 PEPTIDES FOR USE IN THE TREATMENT OF SARCOMA PHARIS BIOTEC GMBH (DE) 2024-11-21 — — WO disclosed
EP-4326774-A1 KIDNEY-GLOMERULAR TARGETED IMMUNOTHERAPY Pandion Operations, Inc. (US) 2024-02-28 — — EP disclosed
CN-105530948-B Peptides having antagonistic activity against natural CXCR4 法瑞斯生物技术有限公司 2023-05-26 — — CN disclosed
EP-4126005-A1 IMMUNOMODULATORY COMPOSITIONS AND USE THEREOF Biond Biologics Ltd. (IL) 2023-02-08 — — EP disclosed
WO-2022226352-A1 KIDNEY-GLOMERULAR TARGETED IMMUNOTHERAPY Pandion Operations, Inc. (US) 2022-10-27 — — WO disclosed
EP-3965825-A1 COMPOSITIONS AND METHODS TO MANUFACTURE PHOSPHATASE AND TENSIN HOMOLOG (PTEN) FUSIONS Therapten Biosciences Inc. (CA) 2022-03-16 — — EP disclosed
Send feedback